Grants Search Results

Graft-versus-host Disease (GvHD) is a common devastating side-effect of bone marrow transplantation. More than 50% of children suffer from moderate to life-threatening GvHD after bone marrow transplantation. GvHD results when the primary leukemia-fighting cells in the transplants become overzealous and begin to attack not only the leukemia, but also the patient’s skin, intestines, liver, and mucosa. Dr. Choi has demonstrated that modulating a gene called interferon gamma receptor in these cells preserves the potent anti-leukemia activities while inhibiting GvHD. Dr. Choi's Rays of Hope St. Baldrick’s Research Grant aims to identify the mechanism underlying the actions of this gene to develop safe and efficient therapeutic strategies.

This grant is named for the Rays of Hope Hero Fund which honors the memory of Rayanna Marrero by giving hope through research funding. She is remembered for her infectious smile and energetic spirit which continue to inspire so many.

Retinoblastoma is a cancer of the eye in children that can cause blindness or death. New therapies are needed to combine with existing drugs to save vision, eyes, and lives. Dr. Corson has developed a new chemical that blocks abnormal blood vessel growth in the eye without side effects. By blocking new blood vessel formation, we could starve a growing retinoblastoma tumor of oxygen and nutrients and stop its growth. To determine this, Dr. Corson's research aims to test this new chemical in a model of retinoblastoma, both alone and in combination with an existing drug.

Medulloblastoma is the most common malignant brain cancer in children. Dr. Erdeich-Epstein's research aims to improve medulloblastoma treatment based on its biology. Dr. Erdeich-Epstein and colleagues have identified PID1 as a candidate tumor suppressor after finding that higher PID1 killed medulloblastoma cells and slowed medulloblastoma growth in models. This research is to examine PID1 further to help develop drugs to improve response of medulloblastoma to treatment.

Over the last decades the introduction of multi-agent chemotherapy protocols have resulted in major advances in the treatment of pediatric acute lymphoblastic leukemia (ALL). However the prognosis of patients whose leukemia relapses after an initial transient response to therapy remains highly unsatisfactory with cure rates of less than 40% despite intensive treatment. Dr. Ferrando's research aims to address fundamental questions on the role and mechanisms of genetic mutations associated with chemotherapy resistance to pave the way for the development of improved therapies for the treatment of relapsed ALL patients.

Although germ cell tumors are the most common solid tumors of adolescents and young adults, care and progress has been hampered by fragmentation between pediatric and adult oncology. No major breakthrough in therapy has occurred for over three decades. Limited genetic understanding hampers researchers' ability to tailor therapy or discover new drugs that could change outcomes. This international consortium of the world's leading scientists and clinicians from both pediatric and medical oncology aim to make significant advances in clinical trial design and genomic understanding of germ cell tumors.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: The Malignant Germ Cell Tumor International Consortium (MaGIC). For a description of this project, see the consortium grant made to the lead institution: Dana-Farber Cancer Institute, Boston, MA.